Land: Irland
Språk: engelska
Källa: HPRA (Health Products Regulatory Authority)
Framycetin sulfate; Aesculin; Cinchocaine Hydrochloride; Hydrocortisone
Opella Healthcare France SAS T/A Sanofi
C05AA; C05AA01
Framycetin sulfate; Aesculin; Cinchocaine Hydrochloride; Hydrocortisone
0.5%w/v+0.5%w/v+1%w/v+1%w/v percent weight/weight
Ointment
Corticosteroids; hydrocortisone
Marketed
1978-04-01
Proctosedyl® Ointment Is this leaflet hard to see or read? Phone 1 4035600 for help. Read all of this leaflet carefully before you start using this medicine - Keep this You may need to read it again - If you have any further questions, ask your doctor or pharmacist - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours If any of the side effects gets or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist In this leaflet: 1. What Proctosedyl ointment is and what it is used for What you need to know before you use Proctosedyl ointment 3. How to use Proctosedyl ointment 4. Possible side effects How to store Proctosedyl ointment 6. Contents of the pack and other information 1. What Proctosedyl ointment is and what it is used for The name of your medicine is Proctosedyl ointment. Proctosedyl ointment contains four different medicines called: hydrocortisone Smg, Cinchocaine hydrochloride 5mg, Framycetin Sulphate 10mg and Aesculin 10mg. Cinchocaine hydrochloride belongs to a group of medicines called local It works by causing numbness in the area to which it is This stops you feeling pain in this area and helps lessen the spasm of the back passage. Hydrocortisone belongs to a group of medicines called corticosteroids It works by lowering the production of substances that cause inflammation. This helps lower swelling, itching and discharge. Proctosedyl ointment can be used for the short-term relief (not more than 7 days) of: - Pain, irritation, discharge and itching associated with enlarged or swollen blood vessels around your back passage (haemorrhoids). - Itching around your back 2. What you need to know you use Proctosedyl ointment Do not use this medicine and tell your doctor if: You are allergic (hypersensitive) to hydrocortisone, cinchocaine hydrochloride, framycetin sulphate, aesculin or any of the other ingredients of Proctosedyl ointment (listed in Section 6 below). I Signs of an allerg Läs hela dokumentet
Health Products Regulatory Authority 29 October 2021 CRN00C5RK Page 1 of 4 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Proctosedyl Ointment 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram of ointment contains 5 mg of Hydrocortisone, 5 mg of Cinchocaine Hydrochlroide, 10 mg of Aesculin and 10 mg of Framycetin Sulphate. Excipients - Contains wool fat 10% w/w For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Ointment. Yellowish white, translucent, homogeneous ointment. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In the local management of pain, pruritus and inflammation associated with internal or external haemorrhoids, and such haemorrhoidal complications as fissures, proctitis, perianal eczema, and post-operative states. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Dosage: Application to external surface or by means of the cannula into the rectum, twice daily and after each bowel movement. Treatment should last for a week. Administration: Topical, Intrarectal and Perianal 4.3 CONTRAINDICATIONS 1. Use in the presence of untreated infections of viral, bacterial, tuberculous, parasitic or fungal origin. 2. Use in patients hypersensitive to the active ingredient or any of the excipients. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Continuous treatment for longer than three weeks should be avoided in patients under the age of three years because of the possibility of adrenocortical suppression and growth retardation. Continuous application without interruption will result in local atrophy of the skin, striae, and superficial vascular dilation. Prolonged use of an anti-infective may result in the development of super-infection due to organisms, including fungi, resistant to that anti-infective. May cause local skin reactions (e.g. contact dermatitis). Before prescribing the product any potential malignancies should be excluded. Health Products Regulatory Authority 29 October 2021 CRN00C5RK Page 2 of 4 Pheochromocytoma crisis, which can be fatal, has been reported afte Läs hela dokumentet